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Responsiveness to Change and Interpretability of the
Simplified Psoriasis Index
Leena Chularojanamontri1,2, Christopher E.M. Griffiths1,3 and Robert J.G. Chalmers1
The Simplified Psoriasis Index (SPI) is a summary measure of psoriasis with separate components for current
severity (weighted for functionally or psychosocially important sites), psychosocial impact, and past behavior.
The current severity components of the professionally assessed SPI (proSPI-s) and self-assessed SPI (saSPI-s)
have each been shown to be valid and reliable. Their responsiveness to change and equivalence to the
current standard (Psoriasis Area and Severity Index, PASI) were investigated. Responsiveness and minimum
clinically important differences (MCIDs) were derived from PASI changes from baseline at weeks 4 (n¼ 100)
and 10 (n¼ 65) in patients commencing therapy for psoriasis. Receiver operating characteristic (ROC) analysis
confirmed that both measures detected responsiveness well (area under the curve (AUC)¼ 0.72–0.96). On
ROC and PASI-based anchor analysis, MCIDs equated to mean absolute and percentage changes of 5 and
60% (proSPI-s), and 7 and 70% (saSPI–s). Satisfactory response as defined byX75% reduction in PASI equated
to 85 and 95% reductions in proSPI–s and saSPI–s, respectively. PASI-equivalent cutoff scores for mild
(PASIo10) and severe (PASI420) psoriasis were o9 and 418 for proSPI–s (n¼ 300) and o10 and 420 for
saSPI–s (n¼ 200; AUC¼ 0.86–0.96). These studies further support the validity of SPI for use in routine clinical
practice.
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INTRODUCTION
There is an unmet need for a reliable measure of psoriasis
severity that is both easy to use and able to capture response to
treatment. In order to document whether the management of
psoriasis is achieving its intended effects, it is essential to
have a reliable means of recording severity, disease impact,
and response to therapeutic intervention. The ideal measure
should represent the true degree of disease severity consis-
tently, minimize inter- and intra-rater variability, detect
changes in disease severity over time (responsiveness), use
the entire range of scale (wide response distribution), and be
easy to administer. A systematic review of clinical psoriasis
measures concluded that none of the 53 different outcome
measures examined excels in all areas. Further, a score in itself
has little or no intrinsic meaning and cannot be interpreted in
isolation (Spuls et al., 2010).
The Psoriasis Area and Severity Index (PASI) is the most
popular clinical measure in clinical trials and is widely used as
the reference standard for any new severity scale for psoriasis.
PASI, however, has many drawbacks, including (i) complex
arithmetic; (ii) the requirement for estimation of body surface
area, which has been shown to have large intra- and inter-rater
variability; (iii) low sensitivity for detecting responsiveness in
limited disease; (iv) low-response distribution, with the upper
half of the scale rarely being used, and (v) lack of standardiza-
tion of cutoff values for mild, moderate, and severe psoriasis
(Spuls et al., 2010; Jensen et al., 2011). The usefulness of PASI
in decision making in clinical practice has been called into
question (van de Kerkhof et al., 2006) and there is a pressing
need for better instruments. Nevertheless, because of its
dominance in reporting response to treatment in clinical trials,
PASI is the only available reference standard against which any
new severity scale can be measured.
The Simplified Psoriasis Index (SPI) is closely modeled on
the Salford Psoriasis Index, which was originally devised in the
late 1990s and was intended to provide a concise but holistic
summary of psoriasis severity (Kirby et al., 2000; Chularo-
janamontri et al., 2013). It contains three components, current
severity, psychosocial impact, and historical course, each of
which contributes toward the disease burden of psoriasis but
cannot be simply summated.
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The current severity component of SPI (SPI-s) is the subject
of this paper. It is a composite score that dispenses with the
need for PASI or body surface area estimation and is weighted
to reflect the impact of psoriasis in functionally or psychoso-
cially important areas (van de Kerkhof et al., 2006). The scalp,
face, hands, feet, and anogenital skin may each contribute up
to 10% of the total extent score, which is derived by according
one of three values (absent or minimal(0), ‘‘noticeable’’(1/2),
or extensive(1)) to each of 10 unequal areas. Scoring of plaque
severity is simplified by using a single overall average. The six-
point average plaque severity score removes the need to assess
erythema, scale, and plaque thickness separately. This severity
score (max¼5) multiplied by the extent score (max¼ 10) is
used to derive SPI–s (max¼ 50).
SPI–s is available in two complementary versions intended,
respectively, for use by health professionals (professional
version of the severity component of SPI; proSPI–s) and for
self-assessment by patients (patient self-assessment version
of the severity component of SPI, saSPI–s): both are freely
available online (Chularojanamontri et al., 2013). Apart
from simplification of the language used for saSPI-s, the two
versions are identical. The scores obtained may well diverge,
however, reflecting differences that may exist between
patients’ own assessments of current severity and
assessments made by professionals.
Our previous studies had shown the acceptability, validity,
wide response distribution, and reliability of proSPI–s and
saSPI–s (Chularojanamontri et al., 2013).
Objectives
The current studies were designed to investigate responsive-
ness to change and interpretability (minimum clinically
important difference (MCID) and categorization) of proSPI–s
and saSPI–s.
Responsiveness to change is the ability of an instrument to
detect changes over time. Our experience from pilot studies
had led us to expect that reductions in psoriasis severity
resulting from treatment would be accompanied by corre-
sponding reductions in proSPI–s and saSPI–s scores. We
wished therefore to investigate formally
(a) the ability of proSPI–s, saSPI–s, and PASI to discriminate
between responders and non-responders to therapy. Three
criteria of response were examined for evaluating each
of the three instruments: (i)X50, (ii)X75, and (iii)X90%
reduction in severity score.
Interpretability is the ability of an instrument to be translated
from a quantitative score or change in score, e.g., PASI or 50%
reduction in PASI score (PASI-50), to a qualitative meaning,
e.g., ‘‘mild’’ or ‘‘improvement’’, respectively.
MCID is the smallest difference in score that patients
perceive as important. It has been suggested that PASI-50
correlates significantly with demonstrable improvements in
patients’ quality of life (Carlin et al., 2004), whereas 75 and
90% reductions in PASI scores (PASI-75 and PASI-90,
respectively) represent clinically meaningful responses (Katz,
2005; Reich et al., 2005). We wished to determine
(b) MCID-1 and MCID-2, which are, respectively, the
smallest mean change and percentage reduction in
proSPI–s and saSPI–s, which are readily perceptible to
the patient.
(c) MCID-3, which is the smallest percentage reduction in
proSPI–s and saSPI–s, which may be used to identify
responders.
Categorization means the extent to which categories and/or
cutoff scores may be derived from an instrument. Using the
European Medicines Agency (EMA) definitions of mild, mod-
erate, and severe psoriasis of PASIo10, 10pPASIp20, and
PASI420, respectively, we wished to determine
(d) the PASI-equivalent proSPI–s and saSPI–s cutoff scores
between mild and moderate psoriasis and between mod-
erate and severe psoriasis.
As lower PASI cutoff points have been widely advocated
both for mild and severe psoriasis, we also elected to calculate
(e) the proSPI–s and saSPI–s equivalents for other PASI values,
specifically 5, 15, and 18.
Ranges for moderate psoriasis as defined by PASI are taken
to be those which lie between the cutoff points for mild and
severe psoriasis and will differ according to which PASI cutoff
points are examined.
RESULTS
One hundred patients commencing a new treatment for
chronic plaque psoriasis (53 men; 47 women; mean age,
41±14.6 years) were assessed at baseline and at week 4. A
further 65 were assessed at week 10; the 35 patients who were
assessed at weeks 0 and 4 but not at week 10 had either
already completed their treatment or were lost to follow-up.
The mean baseline scores of PASI, proSPI–s, and saSPI–s
(n¼ 100) were 9.98, 10.06, and 12.34, respectively. The
correlations between professionally assessed scores (PASI
and proSPI–s) for all comparisons (weeks 0, 4, and 10) were
40.7. The correlations between the patient-reported outcome
scores (saSPI–s) and the two professionally assessed scores
(PASI and proSPI–s) were all X0.5. These results indicate that
proSPI–s and saSPI–s are both suitable for responsiveness and
MCID analysis (Table 1).
Responsiveness to change
Receiver operating characteristic (ROC) area under the curve
(AUC) analysis demonstrated that all three instruments
detected response to treatment well for each of the three
criteria of response (X50, X75, and X90% reductions in
scores, respectively), although PASI and proSPI–s discrimi-
nated better than saSPI–s. For all three instruments, there was
greater discrimination between responders and non-respon-
ders using the criterion X75% reduction rather than X50%
reduction in severity score. The discriminative power of the
X90% criterion was little different from that of the X75%
criterion (Table 2).
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Interpretability
As PASI-50 has been shown to correlate with significant
improvement in patients’ quality of life (Carlin et al., 2004),
yet PASI-75 was the smallest change which, in our data,
identified responders well, we investigated patients who had
achieved PASI-50 but not PASI-75 (i.e., improvement but less
than a good response) to derive estimates for MCID-1 (smallest
mean reduction in proSPI–s and in saSPI–s) and MCID-2
(smallest percentage reduction in proSPI–s and saSPI–s). Thirty
of 100 patients assessed at week 4, and 22 of 65 assessed at
week 10 met these criteria.
MCID-1
(i) The MCID-1 values for proSPI–s and saSPI–s derived by
ROC curve analysis were 5.25 (AUC¼0.72) and 7.25
(AUC¼0.69), respectively (Table 3).
Table 1. Mean absolute scores, mean changes in scores, and correlations between PASI, proSPI–s, and saSPI-s
Mean scores PASI proSPI–s saSPI–s
Period 1 (0–4 weeks, n¼100)
Mean score at baseline (SD) 9.98 (6.52) 10.06 (6.67) 12.34 (8.64)
Mean score at week 4 (SD) 5.66 (5.25) 5.26 (5.15) 5.05 (5.98)
Mean score change (SD) 4.18 (5.60) 4.87 (5.24) 7.29 (9.12)
Period 2 (0–10 weeks, n¼ 65)
Mean score at baseline (SD) 10.79 (7.13) 10.99 (7.21) 12.95 (9.09)
Mean score at week 10 (SD) 3.89 (4.49) 3.06 (4.31) 2.78 (4.98)
Mean score change (SD) 6.89 (6.84) 7.93 (7.35) 10.18 (10.35)
Correlations (Spearman’s) proSPI–s: PASI saSPI–s: PASI saSPI–s: proSPI-s
Between scores
Baseline 0.79 0.57 0.68
Score at week 4 0.92 0.59 0.67
Score at week 10 0.92 0.66 0.69
Between changes in scores
Score at week 4 0.73 0.50 0.59
Score at week 10 0.81 0.63 0.74
Abbreviations: PASI, Psoriasis Area and Severity Index; proSPI–s, professional version of the current severity component of the Simplified Psoriasis Index;
saSPI–s, patient self-assessment version of the current severity component of the Simplified Psoriasis Index.
Table 2. Responsiveness to change of proSPI-s, saSPI-s, and PASI
Week 4 (n¼100) Week 10 (n¼ 65)
49 Achieved XPASI-50 30 Achieved XPASI-75 13 Achieved XPASI-90
proSPI–s saSPI–s proSPI–s saSPI–s proSPI–s saSPI–s
0.86 (0.78–0.93) 1 0.72 (0.62–0.82) 1 0.96 (0.91–1.00) 1 0.78 (0.67–0.90) 1 0.90 (0.82–0.99) 1 0.73 (0.59–0.86) 1
59 Achieved XproSPI–s 50 45 Achieved XproSPI–s 75 21 Achieved XproSPI–s 90
PASI saSPI–s PASI saSPI–s PASI saSPI–s
0.85 (0.78–0.93) 1 0.72 (0.61–0.82) 1 0.92 (0.86–0.98) 1 0.79 (0.66–0.92) 1 0.95 (0.90–1.00) 1 0.78 (0.67–0.89) 1
67 Achieved XsaSPI–s 50 49 Achieved XsaSPI–s 75 38 Achieved XsaSPI–s 90
proSPI–s PASI proSPI–s PASI proSPI–s PASI
0.75 (0.65–0.85) 1 0.77 (0.67–0.86) 1 0.86 (0.74–0.98) 1 0.83 (0.70–0.97) 1 0.85 (0.75–0.95) 1 0.80 (0.69–0.91) 1
Abbreviations: PASI, Psoriasis Area and Severity Index; proSPI-s, professional version of the current severity component of the Simplified Psoriasis Index;
saSPI-s, patient self-assessment version of the current severity component of the Simplified Psoriasis Index.
1Area under the curve (95% confidence interval).
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(ii) The MCID-1 values derived by the anchor-based method
were 6.38 (proSPI–s) and 8.83 (saSPI–s) at week 4, and
7.57 (proSPI–s) and 10.43 (saSPI–s) at week 10.
(iii) The MCID-1 values derived by distribution-based meth-
ods were
(a) 0.5 SD at baseline: 3.38 (proSPI–s) and 4.32 (saSPI–s) at
week 4, and 3.60 (proSPI–s) and 4.55 (saSPI–s) at week 10.
(b) 1.0 SEM: 1.76 (proSPI–s) and 3.67 (saSPI–s) at week 4, and
1.90 (proSPI–s) and 3.85 (saSPI–s) at week 10.
The distribution-based analysis suggested that score reductions
in proSPI–s and saSPI–s of o5 points may indicate change.
We propose, however, that the more conservative values for
MCID-1 derived from ROC analysis and supported by anchor-
based methods are more relevant for clinical decision making,
as argued by others (Revicki et al., 2008; Turner et al., 2010).
We therefore recommend that the integers 5 and 7 be used to
define MCID-1 for proSPI–s and saSPI–s, respectively.
MCID-2
ROC analysis demonstrated that 63% (AUC¼ 0.84) and 71%
(AUC¼0.82) reductions in proSPI–s and saSPI–s, respectively,
best defined MCID-2 (Table 3). For practical purposes, we
would recommend that percentage reductions of 60 and 70%
be used to define MCID-2 for proSPI–s and saSPI–s,
respectively.
MCID-3
Thirty of 65 patients achievedXPASI-75 at week 10. The data
from ROC curve statistics showed that 85% reductions in
proSPI–s (sensitivity 83%, specificity 96%) and 95% reduc-
tions in saSPI–s (sensitivity 84%, specificity 71%) are the
smallest percentage reductions required to identify responders
as defined by a PASI-75 response (Table 3).
Categorization
Data from 300 patients with chronic plaque psoriasis (159
men; 141 women; mean age, 47±14.7 years) were used to
study categorization. The percentages with mild, moderate, or
severe psoriasis according to the EMA–PASI-based criteria
were 69, 23, and 8%, respectively. The distributions of PASI,
proSPI–s, and saSPI–s scores are shown in Figure 1. The lowest
possible score of PASI, proSPI–s, and saSPI–s (0) were
obtained in 0.7, 7.7, and 12% of the patients, respectively,
whereas three patients (1.5%) had the highest possible score of
saSPI–s (max¼50). A wide range of scores was obtained for
both proSPI–s and saSPI–s.
PASI-equivalent proSPI–s and saSPI–s cutoff scores
The correlations between proSPI–s and PASI, and between
saSPI–s and PASI were 0.86 and 0.78, respectively. The AUC
ranged from 0.86 to 0.96, which indicated excellent diagnos-
tic utility of proSPI–s and saSPI–s for defining each of the
proposed cutoff points for mild, moderate, and severe psoriasis
(Table 4). Using the EMA definitions, the PASI equivalents for
mild psoriasis for both proSPI–s and saSPI-s were o9.5; for
severe psoriasis they were 417.5 for proSPI–s and 420 for
Table 3. MCID-1, MCID-2, and MCID-3 by ROC curve
analysis
MCID-1
Change in
score Sensitivity Specificity AUC
proSPI–s 4.25 0.70 0.71
0–4 weeks (n¼ 30) 4.75 0.63 0.74 0.72 (0.61–0.83)
5.25 0.60 0.76
4.25 0.73 0.53
0–10 weeks (n¼22) 4.75 0.64 0.61 0.71 (0.51–0.90)
5.25 0.59 0.69
saSPI–s 4.25 0.70 0.53
0–4 weeks (n¼ 30) 4.75 0.60 0.55 0.62 (0.50–0.75)
5.50 0.60 0.61
5.25 0.82 0.61
0–10 weeks (n¼22) 6.50 0.77 0.61 0.69 (0.48–0.90)
7.25 0.59 0.69
MCID-2
Percentage
reduction Sensitivity Specificity AUC
proSPI–s 51.19 0.77 0.78
0–4 weeks (n¼ 30) 55.49 0.70 0.88 0.82 (0.73–0.91)
57.73 0.70 0.82
57.73 0.83 0.69
0–10 weeks (n¼22) 59.17 0.82 0.69 0.84 (0.69–0.98)
62.92 0.73 0.77
saSPI–s 57.29 0.61 0.57
0–4 weeks (n¼ 30) 59.17 0.60 0.59 0.63 (0.51–0.75)
61.82 0.57 0.63
60.74 0.83 0.69
0–10 weeks (n¼22) 64.58 0.78 0.69 0.82 (0.66–0.98)
70.50 0.78 0.77
MCID-3
Percentage
reduction Sensitivity Specificity AUC
proSPI–s 80.63 0.90 0.80 0.96 (0.91–1.00)
83.12 0.90 0.96
84.52 0.83 0.96
saSPI–s 85.91 0.90 0.60 0.78 (0.67–0.90)
92.33 0.83 0.66
94.94 0.84 0.71
Abbreviations: AUC, area under the curve (95% confidence interval); MCID,
minimum clinically important difference; proSPI–s, professional version of
the current severity component of the Simplified Psoriasis Index; saSPI–s,
patient self-assessment version of the current severity component of the
Simplified Psoriasis Index; ROC, receiver operating characteristic.
MCID-1, the smallest mean changes in proSPI–s and saSPI–s readily
perceptible to the patient; MCID-2, the smallest percentage changes in
proSPI–s and saSPI–s readily perceptible to the patient; MCID-3, the smallest
percentage reductions in proSPI–s and saSPI–s, which may be used to
identify responders.
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saSPI-s. We therefore propose that proSPI–s scores of o9,
9–18, and 418 and saSPI–s scores of o10, 10–20, and 420
can be used as equivalents for EMA-defined mild, moderate,
and severe psoriasis, respectively. As less stringent PASI criteria
for defining psoriasis severity have been widely advocated (van
de Kerkhof et al., 2006; Loveman et al. 2009), the proSPI-s and
saSPI-s equivalents of alternative PASI cutoff points (o5,415,
and 418) are shown in Tables 4 and 5.
DISCUSSION
Relatively little data exist on responsiveness, MCID, and
categorization of clinical measures used for psoriasis. Among
53 psoriasis measures assessed by Spuls, responsiveness had
been studied only in the self-administered PASI (SAPASI),
Psoriasis Assessment Severity Score, Psoriasis Exact Area and
Severity Index, and Psoriasis Long-based Area and Severity
Index, and categorization had been studied only in the
SAPASI, Psoriasis Global Assessment (PGA), and Lattice-
System PG. In none of them was an attempt made to define
MCID (Spuls et al., 2010).
For an instrument to be of use in clinical practice and for
clinical trials, it is important that it should be able to detect
response to treatment and should be interpretable. Each PASI,
proSPI–s, and saSPI–s was reassessed in 100 patients at week
4 and in the 65 of this cohort who remained under follow-up
at week 10. The numbers assessed therefore conform to
excellent and good sample sizes, respectively, according to
the COSMIN (COnsensus-based Standards for the selection of
health Measurement INstruments) criteria (Mokkink et al.,
2010). Our study demonstrated that proSPI–s detected
response to treatment very well, whereas saSPI–s performed
well as surrogates both for PASI and proSPI–s. It has been
recommended that determination of MCID should be based
on anchor-based methods, whereas distribution-based
methods can be used as corroboration (Revicki et al., 2008).
As distribution-based approaches are based on statistical
properties of the instrument without reference to changes of
external standards, their usefulness in clinical practice is
questionable. Further, the different criteria for calculating
MCID by distribution methods cause a large variability in
MCID within the instrument (Turner et al., 2010). Using the
ROC approach to maximize the precision of MCID
determination (Turner et al., 2009), we showed that mean
reductions of 5 and 7 in proSPI–s and saSPI–s, respectively,
best characterized MCID-1. There are advantages in using
MCID-2 (percentage reduction in scores), particularly for
patients with either low- or high-initial scores. We showed
that 60 and 70% reductions in proSPI–s and saSPI–s, respec-
tively, best characterized MCID-2 and that, overall, MCID-2
was a better discriminator than MCID-1. It is important to
note why greater percentage reductions in proSPI–s and
saSPI–s (85 and 95%, respectively) were required to reach
MCID-3 than was the case for our anchor, PASI (75%
reduction). Even if a patient responds well to treatment, a
PASI score of zero is rarely attained. On the other hand,
proSPI–s and saSPI–s will be zero if the patient has minimal
residual psoriasis with a zero score for average plaque
severity (‘‘clear or just slight redness or staining’’).
It should be noted that responsiveness and MCID may vary by
population and context. A single MCID may be insufficient for
all study applications (Revicki et al., 2008). Multiple clinically
relevant anchors are recommended to confirm responsiveness
and to determine MCID. Although PASI was the only anchor
that we used in our study, we believe that the MCIDs we have
determined will enable comparison between historical studies
conducted using PASI and future studies conducted using SPI.
Nevertheless, further investigation using other anchors such as
PGA, SAPASI, and Lattice-System PGA in other populations is to
be encouraged to support our conclusions.
It is vital that data deriving from any instrument designed for
measuring disease severity or activity can be interpreted in a
clinically relevant manner by those who are asked to use it. The
wide range of scores and good correlation between PASI and
proSPI–s (r¼ 0.86) and between PASI and saSPI–s (r¼0.78)
support the reliability of the cutoff points we identified for
categorizing patients into mild, moderate, and severe psoriasis
according to the differing PASI-based criteria presented in
Table 4. To facilitate and simplify the use of proSPI and saSPI
for routine clinical use, we propose that the cutoff points we
identified are converted to the nearest integer (Table 5).
There are several limitations to our study of proSPI–s and
saSPI–s, the most obvious of which are the shortcomings of
PASI as an anchor against which to evaluate any new
instrument for measuring psoriasis severity. The fact that the
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Figure 1. The distributions of the professionally assessed (n¼300) and self-assessed (n¼200) severity scores of the Simplified Psoriasis Index (SPI; proSPI–s and
saSPI–s, respectively), and of the mild, moderate, and severe psoriasis categories derived from them using European Medicines Agency’s Psoriasis Area and
Severity Index–based definitions (PASI categorization).
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majority of PASI assessments were performed by one indivi-
dual provides reassurance that this was scored in a consistent
fashion. A further possible limitation is that we opted not to
use distribution methods to determine cutoff points for
psoriasis severity. Nevertheless, the anchor method is likely
to produce less variant estimates of cutoff values than the
distribution method where the same anchor has been used for
comparison (Prinsen et al., 2010).
Table 4. PASI-equivalent proSPI–s and saSPI–s cutoff points
(A) proSPI–s
Mild psoriasis Severe psoriasis
PASIo5 PASIo10 1 PASI415 PASI418 PASI420 1
proSPI–s Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%)
4.5 86 82
5.0 83 85
5.5 82 85
8.5 88 79
9.5 87 84
10 78 84
11.5 96 83
13.75 94 88
14.25 83 88
16.25 96 87
16.5 — — 96 86
17.25 96 89 — —
17.5 — — 96 88
18.75 85 92 — —
19 83 91
AUC 0.93 (0.90–0.97) 0.91 (0.88–0.94) 0.94 (0.91–0.97) 0.96 (0.94–0.98) 0.96 (0.94–0.98)
(B) saSPI–s
Mild psoriasis Severe psoriasis
PASIo5 PASIo10 1 PASI415 PASI418 PASI420 1
saSPI–s Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%) Sens. (%) Spec. (%)
4.5 82 76
5.0 78 82
5.5 76 82
8.5 83 79
9.5 83 83
10 78 83
17.25 82 87
18.5 82 89 83 86
19.25 77 89 83 86
19.5 — — 89 85
19.75 83 87 — —
20 — — 89 86
20.5 75 88 78 88
AUC 0.91 (0.87–0.95) 0.86 (0.80–0.92) 0.91 (0.83–0.98) 0.90 (0.78–1.00) 0.95 (0.87–1.00)
Abbreviations: AUC, Area under the curve (95% confidence interval), PASI, Psoriasis Area and Severity Index; proSPI-s, professional version of the current
severity component of the Simplified Psoriasis Index; saSPI-s, patient self-assessment version of the current severity component of the Simplified Psoriasis Index;
Sens., sensitivity; Spec., specificity.
Black-rule separation between the numerals indicate where proSPI–s and saSPI–s data points are not displayed.
1European Medicines Agency–recommended cutoff points for mild and severe psoriasis.
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Although interpretability of PASI has never been system-
atically evaluated, both responsiveness to change and inter-
pretability of the severity component of SPI are now defined.
We believe that the present studies provide further evidence to
support the introduction of SPI in both its professional (proSPI)
and patient self-assessed (saSPI) versions into routine clinical
practice.
MATERIALS AND METHODS
The COSMIN (COnsensus-based Standards for the selection of health
Measurement INstruments) checklist was used to evaluate the metho-
dological quality of this study (Mokkink et al., 2010). Adult patients
with chronic plaque psoriasis attending a National Health Service
tertiary referral psoriasis centre in Manchester, UK, were invited to
participate and gave their consent to do so. The proSPI–s and saSPI–s
were each available as a single-side English language–printed pro-
forma. The responsiveness to change and MCID of proSPI–s and saSPI–
s were investigated in 100 patients about to start and 4 weeks after
starting treatment for psoriasis; the interventions included photother-
apy, methotrexate, ciclosporin, acitretin, and biological agents. A third
assessment was undertaken in those patients still under follow-up at
week 10. All PASI and proSPI–s assessments were completed by author
LC, whereas saSPI–s was completed by each patient individually.
Three hundred paired assessments of proSPI–s and PASI completed
by the authors (LC, CEMG, and RJGC) were used to determine PASI-
equivalent proSPI–s cutoff scores. PASI-equivalent saSPI–s cutoff
scores were derived from concomitant patient self-assessed severity
measurements (saSPI–s) available for all but the first 100 assessments.
The study involved the use of questionnaires and assessment forms
already in routine clinical use in our department. Institutional
approval and patient consent were thus not required. The study was
conducted according to the Declaration of Helsinki Principles.
Statistical analysis
In order to assess the suitability of our data for further analysis, we first
examined the relationships between PASI, proSPI–s, and saSPI–s using
Spearman’s correlation. Only if at least a moderate degree of
correlation (rX0.4) was confirmed, did we undertake analysis of
responsiveness to change, MCID, and cutoff scores (Revicki et al.,
2008, Prinsen et al., 2010). From our previous studies, we expected
the correlations between proSPI–s and PASI, and between proSPI–s
and saSPI–s to be higher than that between saSPI–s and PASI
(Chularojanamontri et al., 2013).
Responsiveness and MCID were investigated using ROC curve
analysis. The AUC was used to investigate the ability of SPI-s to
discriminate between responders and non-responders: the larger the
AUC, the better the discrimination. An AUC of 1 is considered
perfect, whereas AUCs of 0.5, 0.7, 0.8, and 0.9 are considered no
better than chance, fair, good, and excellent, respectively (Hanley,
1988). Responsiveness was investigated using 50% reduction in
scores at week 4, and 75 and 90% reductions in scores at week 10
as the response criteria for all three instruments. ROC curve analysis
was used to determine the criterion that best discriminated response
from non-response.
The absolute and percentage reductions in proSPI–s and saSPI–s
scores of patients who achieved at least improvement (PASI-50;
Carlin et al., 2004) but less than the smallest change that satisfactorily
identified good response (as identified by ROC curve analysis of PASI
response) were used to define MCID-1 and MCID-2, respectively, for
each instrument. Similarly, the smallest change that satisfactorily
identified responders (PASI-75 or PASI-90) at week 10 was used to
define MCID-3. The sensitivity and specificity over the range of
absolute and percentage reductions in scores were determined for
each instrument by ROC curve analysis.
In addition to ROC curve analysis, distribution-based and anchor-
based methods were used to define MCID. Distribution methods rely
on the statistical distribution of values. A number of different criteria
have been proposed for defining MCID from analysis of distribution:
0.5 SD at baseline and 1.0 SEM have been the most widely
adopted (Wyrwich and Wolinsky, 2000; Turner et al., 2010). SEM
is derived from the baseline SD by the formula SEM¼ SD at baseline
 (1 reliability of the instrument)1/2, originally using Cronbach’s
alpha test but more recently using a test–retest correlation (Beaton
et al., 2010). The test–retest correlations for proSPI–s and saSPI–s
were derived from our previous study (proSPI–s¼ 0.93 and
saSPI–s¼ 0.82; Chularojanamontri et al., 2013). The anchor method
was employed to evaluate changes in proSPI–s and saSPI–s using PASI
as the anchor: mean reductions of proSPI–s and saSPI–s scores were
compared with mean reductions in PASI scores over the observation
periods 0–4 weeks and 0–10 weeks. The results from the various
different methods were used to examine the consistency of the data:
mean score change and ROC curve analysis were selected to define
MCID-1.
The EMA definitions of mild, moderate, and severe psoriasis
(PASIo10, 10pPASIp20, and PASI420, respectively) were used
to define anchor points for our study (Naldi, 2010). We examined
PASIo5, PASI415, and PASI418 as further anchor points, as these
have been variously proposed as more suitable cutoff points for, on
the one hand, identifying patients with limited psoriasis who may
nevertheless need systemic or phototherapy (van de Kerkhof et al.,
2006), and, on the other hand, for defining psoriasis as severe. ROC
curve analysis was used to determine the sensitivity and specificity of
a range of potential cutoff points. The value with the best fit for
sensitivity and specificity on ROC curve analysis was selected as the
score that most accurately discriminated between each clinical
severity level.
Statistical Package for the Social Sciences version 17, Chicago, IL;
SPSS, was used for Spearman’s correlation and ROC curve analysis.
Table 5. Proposed practical proSPI–s and saSPI–s PASI
equivalents
Mild psoriasis Severe psoriasis
PASIo5 PASIo10 1 PASI415 PASI418 PASI420 1
proSPI-s o5 o9 413 417 418
saSPI-s o5 o10 418 419 420
Abbreviations: PASI, Psoriasis Area and Severity Index; proSPI-s, profes-
sional version of the current severity component of the Simplified Psoriasis
Index; saSPI-s, patient self-assessment version of the current severity
component of the Simplified Psoriasis Index.
The proSPI–s and saSPI–s PASI-equivalent ranges for moderate psoriasis are
intermediate and, using the European Medicines Agency (EMA) criteria,
would thus be 9–18 and 10–20, respectively.
1European Medicines Agency–recommended cutoff points for mild and
severe psoriasis.
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